weight loss eli lilly

Order byBest matchMost fresh

Eli Lilly hikes Mounjaro prices in the UK

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss.

· 1d · on MSN

Eli Lilly hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US

· 1d · on MSN

Lilly to hike UK price of Mounjaro weight-loss drug by 170%

· 20h

Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments wanes and Donald Trump’s tariff and price-cut threats weigh on the pharmaceut...

· 21h

Company hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US

STAT · 1d

Pharmalittle: We’re reading about Lilly boosting prices in Europe, HHS reviving a vaccine task force, and more

Healthline2d

Orforglipron: What to Know About Eli Lilly’s New Weight Loss Pill for Obesity

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.